Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium glycerophosphate is a calcium salt of glycerophosphoric acid used as a mineral salt and acid-neutralizing agent. Public sources identify it both as the active ingredient in AkPharma's Prelief products, which are marketed to reduce the acidity of foods and beverages, and as the investigational ingredient in an AkPharma intranasal wash studied for symptomatic relief of allergic rhinitis. Mechanistically, it does not act through a well-defined receptor target; rather, it functions primarily through physicochemical buffering and mineral supplementation, providing calcium and phosphate/glycerophosphate and reducing acidity in the local environment. It is best characterized as a small-molecule mineral salt rather than a targeted pharmaceutical asset. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01647633))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium glycerophosphate.